Ticagrelor or Prasugrel for Acute Patients Who Undergo Angioplasty

We are still asking the same question: ticagrelor or prasugrel? With narrow margins between these drugs in terms of efficacy and bleeding, it is difficult to decide which to prescribe.

Ticagrelor o prasugrel en pacientes agudos que reciben angioplastia

While it has certain methodological limitations, this research published in JAMA seems to clarify the picture at least for patients with acute coronary syndromes who undergo angioplasty.

This pre-specified post-randomization analysis included a subgroup of 3377 patients with acute coronary syndrome. Patients were randomized to receive ticagrelor or prasugrel prior to angioplasty.

The primary endpoint was a composite of all-cause mortality, myocardial infarction, or stroke at 12 months. The primary safety endpoint was BARC 3-5 bleeding.

Both arms, ticagrelor (n = 1676) and prasugrel (n = 1701), were well matched for clinical characteristics. 

The primary endpoint occurred in 9.8% of patients in the ticagrelor arm vs. 7.1% in the prasugrel arm (hazard ratio: 1.41; 95% confidence interval: 1.11-1.78; p = 0.005). Prasugrel was also better when considering infarction only (5.3% vs. 3.8%, p = 0.03)


Read also: Novel DES Technology Promises to Become the Next DES Generation.


Researchers expected ticagrelor to perhaps compensate for thrombotic events due to its historical safety as regards bleeding (carried over from the PLATO study), but this was not the case: both drugs had similar rates of BARC 3-5 bleeding (5.3% vs 4.9%; p = 0.54).

Conclusion

In patients with acute coronary syndrome who undergo angioplasty, the incidence of the primary endpoint was less frequent among those who received prasugrel, with no incidence on bleeding.

This places prasugrel as a superior strategy, although not definitely; observations are from a post-randomization subgroup, so further dedicated studies are required to reach a final conclusion.

jamacardiology-coughlan-2021-oi-210043-1623426142-46029

Original Title: Ticagrelor or Prasugrel for Patients With Acute Coronary Syndrome Treated With Percutaneous Coronary Intervention. A Prespecified Subgroup Analysis of a Randomized Clinical Trial.

Reference: J. J. Coughlan et al. JAMA Cardiol. 2021 Jun 30. Online ahead of print. doi: 10.1001/jamacardio.2021.2228. 


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....